

Thomas R Chauncey

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8529277/publications.pdf>

Version: 2024-02-01

170
papers

12,969
citations

32410

55
h-index

25983

112
g-index

170
all docs

170
docs citations

170
times ranked

6319
citing authors

#	ARTICLE	IF	CITATIONS
1	Androgens and estrogens predict sexual function after autologous hematopoietic stem cell transplant in men. <i>Andrology</i> , 2022, 10, 291-302.	1.9	3
2	Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: Improved outcomes over two decades. <i>Haematologica</i> , 2021, 106, 1599-1607.	1.7	18
3	Ibrutinib Monotherapy in Relapsed or Refractory, Transformed Diffuse Large B-cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 176-181.	0.2	8
4	Long-term Outcomes with Nonmyeloablative HLA-Identical Related Hematopoietic Cell Transplantation Using Tacrolimus and Mycophenolate Mofetil for Graft-versus-Host Disease Prophylaxis. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 163.e1-163.e7.	0.6	0
5	Autologous hematopoietic transplantation following COVID-19 infection. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, 1167-1170.	0.2	2
6	Proteogenomic Characterization of Highly Enriched Viable Leukemic Blasts in Acute Myeloid Leukemia: A SWOG Report. <i>Blood</i> , 2021, 138, 522-522.	0.6	0
7	Phase I/II multisite trial of optimally dosed clofarabine and low-dose TBI for hematopoietic cell transplantation in acute myeloid leukemia. <i>American Journal of Hematology</i> , 2020, 95, 48-56.	2.0	5
8	Rituximab-based allogeneic transplant for chronic lymphocytic leukemia with comparison to historical experience. <i>Bone Marrow Transplantation</i> , 2020, 55, 172-181.	1.3	10
9	Venetoclax and Decitabine for T/Myeloid Mixed-Phenotype Acute Leukemia Not Otherwise Specified (MPAL NOS). <i>Case Reports in Hematology</i> , 2020, 2020, 1-4.	0.3	10
10	AML risk stratification models utilizing ELN-2017 guidelines and additional prognostic factors: a SWOG report. <i>Biomarker Research</i> , 2020, 8, 29.	2.8	22
11	Sirolimus with CSP and MMF as GVHD prophylaxis for allogeneic transplantation with HLA antigen mismatched donors. <i>Blood</i> , 2020, 136, 1499-1506.	0.6	16
12	Mantle cell lymphoma relapsed after autologous stem cell transplantation: a single-center experience. <i>Blood Research</i> , 2020, 55, 57-61.	0.5	1
13	Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2019, 6, e409-e418.	2.2	84
14	Assessing Cachexia Acutely after Autologous Stem Cell Transplant. <i>Cancers</i> , 2019, 11, 1300.	1.7	11
15	Total body irradiation dose escalation decreases risk of progression and graft rejection after hematopoietic cell transplantation for myelodysplastic syndromes or myeloproliferative neoplasms. <i>Haematologica</i> , 2019, 104, 1221-1229.	1.7	14
16	Second allogeneic hematopoietic cell transplantation for relapse after first allografts. <i>Leukemia and Lymphoma</i> , 2019, 60, 1758-1766.	0.6	12
17	Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma. <i>Haematologica</i> , 2019, 104, 380-391.	1.7	25
18	Impact of Neurocognitive Dysfunction in a Veteran Population Undergoing First Outpatient Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. <i>Blood</i> , 2019, 134, 5883-5883.	0.6	0

#	ARTICLE	IF	CITATIONS
19	Ibrutinib in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma: Final Results from a Prospective Phase II Study. <i>Blood</i> , 2019, 134, 1596-1596.	0.6	1
20	Development and Performance of Risk Stratification Models for AML Patients Utilizing ELN-2017 Guidelines and Additional Prognostic Factors: A SWOG Report. <i>Blood</i> , 2019, 134, 2691-2691.	0.6	0
21	Sirolimus Combined with Cyclosporine (CSP) and Mycophenolate Mofetil (MMF) As Graft-Vs-Host Disease (GVHD) Prophylaxis after Nonmyeloablative (NMA) Hematopoietic Cell Transplantation (HCT) Using HLA Class I or Class II Antigen Mismatched Donors: Results from a Phase II Multi-Center Trial. <i>Blood</i> , 2019, 134, 369-369.	0.6	0
22	Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studies. <i>Blood</i> , 2018, 131, 2782-2788.	0.6	18
23	Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 308-313.	2.0	6
24	Impact of Specimen Heterogeneity on Biomarkers in Repository Samples from Patients with Acute Myeloid Leukemia: A SWOG Report. <i>Biopreservation and Biobanking</i> , 2018, 16, 42-52.	0.5	6
25	Ibrutinib Is Effective in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma: Results from a Prospective Phase II Study. <i>Blood</i> , 2018, 132, 2954-2954.	0.6	0
26	Allogeneic Hematopoietic Cell Transplantation (HCT) in the Eighth Decade of Life: How Much Does Age Matter?. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, S98-S99.	2.0	2
27	CD25 Blockade Delays Regulatory T Cell Reconstitution and Does Not Prevent Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 405-411.	2.0	11
28	Comorbidities, Alcohol Use Disorder, and Age Predict Outcomes after Autologous Hematopoietic Cell Transplantation for Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1582-1587.	2.0	20
29	Pretransplantation Minimal Residual Disease Predicts Survival in Patients with Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation in Complete Remission. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 380-385.	2.0	37
30	Sirolimus Combined with Mycophenolate Mofetil (MMF) and Cyclosporine (CSP) Significantly Improves Prevention of Acute Graft-Versus-Host-Disease (GVHD) after Unrelated Hematopoietic Cell Transplantation (HCT): Results from a Phase III Randomized Multi-Center Trial. <i>Blood</i> , 2016, 128, 506-506.	0.6	3
31	Adding peri-transplant rituximab to nonmyeloablative (NMA) conditioning before allogeneic hematopoietic cell transplantation (allo-HCT) to improve disease-related outcomes in patients with chronic lymphocytic leukemia (CLL): Phase II clinical trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, 7052-7052.	0.8	0
32	Reversal of Low Donor Chimerism Following Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion. <i>Blood</i> , 2016, 128, 2215-2215.	0.6	0
33	Comparable Outcomes of Patients Eligible Versus Ineligible for Southwest Oncology Group (SWOG) Leukemia Studies. <i>Blood</i> , 2016, 128, 4002-4002.	0.6	0
34	Improved Prognostic Significance of Genomic and Transcriptional Biomarkers By Examining Enriched Populations of AML Blasts: A SWOG Report. <i>Blood</i> , 2016, 128, 2890-2890.	0.6	0
35	Pretransplant Minimal Residual Disease (MRD) Positivity Independently Predicts Survival in a Unselected Cohort of Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation in Complete Remission. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S131-S132.	2.0	0
36	High-dose CD20-targeted radioimmunotherapy-based autologous transplantation improves outcomes for persistent mantle cell lymphoma. <i>British Journal of Haematology</i> , 2015, 171, 788-797.	1.2	11

#	ARTICLE	IF	CITATIONS
37	Long-term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. <i>Cancer</i> , 2015, 121, 3709-3716.	2.0	27
38	Long-Term Outcomes of Patients with Advanced Mantle Cell Lymphoma Treated with Allogeneic Hematopoietic Cell Transplantation after Nonmyeloablative Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S88-S89.	2.0	0
39	Fibrosing Cholestatic Hepatitis C After Hematopoietic Cell Transplantation. <i>American Journal of Surgical Pathology</i> , 2015, 39, 212-220.	2.1	26
40	Autologous transplant for relapsed follicular lymphoma: impact of pre-transplant rituximab sensitivity. <i>Leukemia and Lymphoma</i> , 2015, 56, 92-96.	0.6	5
41	A Prospective Multicenter Study of Nonmyeloablative Conditioning with TBI or Fludarabine/TBI for HLA-Matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies with Post Grafting Immunosuppression with Tacrolimus and Mycophenolate Mofetil: 10-Year Experience. <i>Blood</i> , 2015, 126, 1949-1949.	0.6	1
42	Comorbidity, History of Alcohol Disorders, and LDH Predict Non-Relapse Mortality (NRM) Among Recipients of Autologous Hematopoietic Cell Transplantation (HCT) for Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S66-S67.	2.0	1
43	<scp>CD</scp>20-positive plasmablastic lymphoma with excellent response to bortezomib combined with rituximab. <i>European Journal of Haematology</i> , 2014, 93, 77-80.	1.1	34
44	A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation. <i>Haematologica</i> , 2014, 99, 1624-1631.	1.7	33
45	Rituximab Maintenance Therapy after Autologous Stem Cell Transplantation Improves Survival of Patients with Mantle Cell Lymphoma. <i>Blood</i> , 2014, 124, 3985-3985.	0.6	2
46	Long Term Follow-up of High-Dose CD20-Targeted Radioimmunotherapy-Based Autologous Transplantation for Patients with Mantle Cell Lymphoma. <i>Blood</i> , 2014, 124, 3967-3967.	0.6	3
47	Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial CD3+ T Cell Dose. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 949-957.	2.0	79
48	Fludarabine and 2-Gy TBI is Superior to 2ÂGy TBI as Conditioning for HLA-Matched Related Hematopoietic Cell Transplantation: A Phase III Randomized Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1340-1347.	2.0	23
49	Specific Features Identify Patients with Relapsed or Refractory Mantle Cell Lymphoma Benefitting from Autologous Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1403-1406.	2.0	25
50	Graft-Versus-Host Disease and Graft-Versus-Tumor Effects After Allogeneic Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2013, 31, 1530-1538.	0.8	197
51	Umbilical Cord Blood Transplant Patients At High Risk Of Graft Rejection Achieve Early Full Donor Chimerism When 300cGy Is Used In The Reduced Intensity Conditioning Regimen. <i>Blood</i> , 2013, 122, 697-697.	0.6	3
52	Impact Of Pre-Transplant Rituximab Sensitivity In Relapsed Follicular Lymphoma On Outcome After Autologous Transplant. <i>Blood</i> , 2013, 122, 3365-3365.	0.6	7
53	The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation. <i>Blood</i> , 2012, 119, 2657-2664.	0.6	133
54	Long-term outcomes after transplantation of HLA-identical related G-CSFâ€mobilized peripheral blood mononuclear cells versus bone marrow. <i>Blood</i> , 2012, 119, 2675-2678.	0.6	54

#	ARTICLE	IF	CITATIONS
55	Cytomegalovirus Viral Load and Virus-Specific Immune Reconstitution after Peripheral Blood Stem Cell versus Bone Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 66-75.	2.0	25
56	Limiting the Daily Total Nucleated Cell Dose of Cryopreserved Peripheral Blood Stem Cell Products for Autologous Transplantation Improves Infusion-Related Safety with No Adverse Impact on Hematopoietic Engraftment. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 220-228.	2.0	14
57	Early Results of a Phase II Study Adding Peri-Transplant Rituximab to Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation (HCT) for Patients (PTS) with High-Risk Fludarabine-Refractory Chronic Lymphocytic Leukemia (CLL). <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, S289-S290.	2.0	0
58	Allo-SCT for multiple myeloma: a review of outcomes at a single transplant center. <i>Bone Marrow Transplantation</i> , 2012, 47, 1312-1317.	1.3	23
59	Randomized Comparison of Melphalan 200 Mg/m ² v. 280 Mg/m ² As a Preparative Regimen for Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. <i>Blood</i> , 2012, 120, 2009-2009.	0.6	1
60	The Anti-CD25 Antibody Daclizumab Delays Treg Reconstitution, Promotes CD4 Memory, and Does Not Prevent Acute or Chronic Gvhd After Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2012, 120, 4195-4195.	0.6	1
61	Second Allogeneic Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies for Relapse After First Allografts. <i>Blood</i> , 2012, 120, 4207-4207.	0.6	1
62	Specific Features Identify Patients with Relapsed/Refractory Mantle Cell Lymphoma Benefitting From Autologous Hematopoietic Cell Transplantation. <i>Blood</i> , 2012, 120, 3082-3082.	0.6	0
63	Donor Lymphocyte Infusion for Relapsed Hematological Malignancies After Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial CD3+ T Cell Dose. <i>Blood</i> , 2012, 120, 354-354.	0.6	0
64	Mantle Cell Lymphoma International Prognostic Index but Not Pretransplantation Induction Regimen Predicts Survival for Patients With Mantle-Cell Lymphoma Receiving High-Dose Therapy and Autologous Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2011, 29, 3023-3029.	0.8	66
65	Long-term Outcomes Among Older Patients Following Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation for Advanced Hematologic Malignancies. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 1874.	3.8	274
66	Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia. <i>Haematologica</i> , 2011, 96, 1113-1120.	1.7	95
67	Transplantation of Peripheral Blood Cells As Compared with Bone Marrow From HLA-Identical Related Donors Is Associated with Superior Long-Term Outcomes. <i>Blood</i> , 2011, 118, 319-319.	0.6	22
68	The Pre-Transplant Mantle Cell Lymphoma International Prognostic Index Predicts Overall and Progression-Free Survival Following High-Dose Therapy and Autologous Stem Cell Transplant for Mantle Cell Lymphoma. <i>Blood</i> , 2011, 118, 2026-2026.	0.6	1
69	Prognostic Import of French-American-British (FAB) System As Embedded in 2008 Revision of World Health Organization Classification of AML: Review of SWOG Data. <i>Blood</i> , 2011, 118, 1446-1446.	0.6	0
70	Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2010, 148, 48-58.	1.2	26
71	Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2010, 28, 2859-2867.	0.8	191
72	Low-Dose Total Body Irradiation and Fludarabine Conditioning for HLA Class I-Mismatched Donor Stem Cell Transplantation and Immunologic Recovery in Patients with Hematologic Malignancies: A Multicenter Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 384-394.	2.0	39

#	ARTICLE	IF	CITATIONS
73	Impacts of Cytogenetic Abnormalities and Prior Alemtuzumab on Outcomes of Patients (pts) with High-Risk Chronic Lymphocytic Leukemia (CLL) Given Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT). <i>Blood</i> , 2010, 116, 2364-2364.	0.6	2
74	International Working Group Scores Predict Post-Transplant Outcomes In Patients with Myelofibrosis. <i>Blood</i> , 2010, 116, 3085-3085.	0.6	5
75	A Relapse Risk Score to Predict Acute Myeloid Leukemia Relapse After Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation Based on Pre-Transplant Variables.. <i>Blood</i> , 2010, 116, 3450-3450.	0.6	1
76	Outcomes Following Relapse of Non-Hodgkin Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL) After Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation (HCT) From HLA-Matched Related or Unrelated Donors. <i>Blood</i> , 2010, 116, 1292-1292.	0.6	0
77	Sequential Autologous Followed by Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT) From HLA-Matched Related or Unrelated Donors Improves Outcomes of Patients (pts) with Bulky Lymphoma or Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2010, 116, 2365-2365.	0.6	5
78	Tandem Autologous and Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT) from HLA-matched Related Or Unrelated Donors for Advanced Lymphoma Or Chronic Lymphocytic Leukemia (CLL). <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 66.	2.0	2
79	What Is the Role for Donor Natural Killer Cells after Nonmyeloablative Conditioning?. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 580-588.	2.0	52
80	Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting. <i>Blood</i> , 2009, 113, 3383-3391.	0.6	106
81	A Randomized 3-Arm Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute Graft-Versus-Host Disease (GVHD) After Unrelated Donor Hematopoietic Cell Transplantation (HCT) Using Nonmyeloablative Conditioning for Patients with Hematologic Malignancies: A Multi-Center Trial.. <i>Blood</i> , 2009, 114, 348-348.	0.6	4
82	Hematopoietic cell transplantation's comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation. <i>Cancer</i> , 2008, 112, 1992-2001.	2.0	233
83	Nonmyeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience. <i>British Journal of Haematology</i> , 2008, 143, 395-403.	1.2	97
84	Reduced-Intensity Conditioning followed by Allogeneic Hematopoietic Cell Transplantation for Adult Patients with Myelodysplastic Syndrome and Myeloproliferative Disorders. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 246-255.	2.0	133
85	Pretransplant Neutropenia Is Associated with Poor-Risk Cytogenetic Features and Increased Infection-Related Mortality in Patients with Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 799-806.	2.0	23
86	Five-Year Follow-Up of Patients With Advanced Chronic Lymphocytic Leukemia Treated With Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning. <i>Journal of Clinical Oncology</i> , 2008, 26, 4912-4920.	0.8	257
87	Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Relapsed, Refractory, and Transformed Indolent Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 211-217.	0.8	186
88	Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Patients with De Novo and Secondary Acute Myeloid Leukemia. <i>Blood</i> , 2008, 112, 149-149.	0.6	4
89	Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. <i>Blood</i> , 2007, 110, 2744-2748.	0.6	156
90	Nonmyeloablative Unrelated Donor Hematopoietic Cell Transplantation to Treat Patients with Poor-Risk, Relapsed, or Refractory Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 423-432.	2.0	40

#	ARTICLE	IF	CITATIONS
91	368: Longer follow up of patients (pts) with advanced chronic lymphocytic leukemia (CLL) treated with nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation (HCT). <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 133-134.	2.0	3
92	Extended Mycophenolate Mofetil and Shortened Cyclosporine Failed to Reduce Graft-versus-Host Disease after Unrelated Hematopoietic Cell Transplantation with Nonmyeloablative Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 1041-1048.	2.0	19
93	Long-Term Outcome of Autologous Followed by Nonmyeloablative Allografting from HLA-Identical Sibling for Multiple Myeloma (MM).. <i>Blood</i> , 2007, 110, 3029-3029.	0.6	2
94	Outcomes of Allogeneic Hematopoietic Cell Transplantation (HCT) after Non-Myeloablative Conditioning in Relapsed Diffuse Large B-Cell Lymphoma (DLBCL).. <i>Blood</i> , 2007, 110, 3037-3037.	0.6	0
95	Duration of Immunosuppressive Therapy for Chronic Graft-vs.-Host Disease (cGVHD) Following Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation (HCT).. <i>Blood</i> , 2007, 110, 1071-1071.	0.6	0
96	Treatment for Acute Myelogenous Leukemia by Low-Dose, Total-Body, Irradiation-Based Conditioning and Hematopoietic Cell Transplantation From Related and Unrelated Donors. <i>Journal of Clinical Oncology</i> , 2006, 24, 444-453.	0.8	243
97	Treatment for acute myelogenous leukemia by low dose Total Body Irradiation (TBI) based conditioning and hematopoietic cell transplantation from related and unrelated donors. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 31-32.	2.0	115
98	Unrelated Donor Granulocyte Colony-Stimulating Factorâ€“Mobilized Peripheral Blood Mononuclear Cell Transplantation after Nonmyeloablative Conditioning: The Effect of Postgrafting Mycophenolate Mofetil Dosing. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 454-465.	2.0	83
99	Extending Postgrafting Cyclosporine Decreases the Risk of Severe Graft-versus-Host Disease after Nonmyeloablative Hematopoietic Cell Transplantation. <i>Transplantation</i> , 2006, 81, 818-825.	0.5	38
100	Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. <i>Leukemia</i> , 2006, 20, 128-135.	3.3	220
101	Factors Associated With Outcomes in Allogeneic Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning After Failed Myeloablative Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2006, 24, 4150-4157.	0.8	104
102	Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT) for Refractory Waldenstromâ€™s Macroglobulinemia (WM): Evidence for a Graft-Versus-WM Effect.. <i>Blood</i> , 2006, 108, 3034-3034.	0.6	4
103	Outcomes of c Hematopoietic Stem Cell Transplantation (HCT) after Non-Myeloablative Conditioning in Relapsed, Refractory, or Transformed Indolent Non-Hodgkin Lymphoma (NHL).. <i>Blood</i> , 2006, 108, 3124-3124.	0.6	1
104	Postgrafting Immunosuppression with Prolonged Mycophenolate Mofetil (MMF) and Truncated Cyclosporine (CSP) Failed To Reduce the Incidence of Graft-Versus-Host Disease (GVHD) after Unrelated Donor Hematopoietic Cell Transplantation (HCT) with Nonmyeloablative Conditioning.. <i>Blood</i> , 2006, 108, 3119-3119.	0.6	0
105	Allogeneic peripheral blood stem cell graft composition affects early T-cell chimaerism and later clinical outcomes after non-myeloablative conditioning. <i>British Journal of Haematology</i> , 2005, 128, 659-667.	1.2	58
106	Prognostic relevance of 'early-onset' graft-versus-host disease following non-myeloablative haematopoietic cell transplantation. <i>British Journal of Haematology</i> , 2005, 129, 381-391.	1.2	41
107	Cyclophosphamide and antithymocyte globulin as a conditioning regimen for allogeneic marrow transplantation in patients with aplastic anaemia: a long-term follow-up. <i>British Journal of Haematology</i> , 2005, 130, 747-751.	1.2	99
108	High doses of transplanted CD34+ cells are associated with rapid T-cell engraftment and lessened risk of graft rejection, but not more graft-versus-host disease after nonmyeloablative conditioning and unrelated hematopoietic cell transplantation. <i>Leukemia</i> , 2005, 19, 822-828.	3.3	96

#	ARTICLE	IF	CITATIONS
109	Hematopoietic cell transplantation from HLA-identical sibling donors after low-dose radiation-based conditioning for treatment of CML. <i>Leukemia</i> , 2005, 19, 990-997.	3.3	57
110	Graft-Versus-Tumor Effects After Allogeneic Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning. <i>Journal of Clinical Oncology</i> , 2005, 23, 1993-2003.	0.8	312
111	Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning for Advanced Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2005, 23, 3819-3829.	0.8	214
112	Randomized trial of allogeneic related bone marrow transplantation versus peripheral blood stem cell transplantation for chronic myeloid leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 85-92.	2.0	54
113	Assessing donor chimerism level among CD3 T, CD4 T, CD8 T, and NK cells predicts subsequent graft rejection, GVHD, and relapse after allogeneic HCT with nonmyeloablative conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 11.	2.0	6
114	HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with chronic myeloid leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 272-279.	2.0	48
115	Effects of race on survival after stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 231-239.	2.0	56
116	Targeted Busulfan and Cyclophosphamide as Compared to Busulfan and TBI as Preparative Regimens for Transplantation in Patients with Advanced MDS or Transformation to AML. <i>Leukemia and Lymphoma</i> , 2004, 45, 2409-2418.	0.6	27
117	Autologous bone marrow transplantation improves disease free survival but not overall survival in people with acute myeloid leukaemia. <i>Cancer Treatment Reviews</i> , 2004, 30, 483-487.	3.4	1
118	HLA-matched related (MRD) or unrelated donor (URD) nonmyeloablative conditioning and hematopoietic cell transplant (HCT) for patients with advanced Hodgkin disease (HD). <i>Biology of Blood and Marrow Transplantation</i> , 2004, 10, 73-74.	2.0	68
119	Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. <i>Blood</i> , 2004, 103, 790-795.	0.6	124
120	Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. <i>Blood</i> , 2004, 104, 2254-2262.	0.6	226
121	Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. <i>Blood</i> , 2004, 104, 3535-3542.	0.6	248
122	Transplantation for adult ALL—typing and timing. <i>Blood</i> , 2004, 104, 2998-2999.	0.6	1
123	Unrelated Donor Peripheral Blood Stem Cell (PBSC) Transplantation Using Nonmyeloablative Conditioning and Mycophenolate Mofetil (MMF) TID Results in High Engraftment Rates.. <i>Blood</i> , 2004, 104, 1818-1818.	0.6	4
124	Conversion of Low Donor Chimerism Following Nonmyeloablative Conditioning for Hematopoietic Cell Transplantation (HCT) Using Pentostatin and Donor Lymphocyte Infusion (DLI).. <i>Blood</i> , 2004, 104, 186-186.	0.6	4
125	Higher Doses of Transplanted CD34+, CD3+ and CD8+ Cells Are Associated with Better Donor T-Cell Chimerism and Less Graft Rejection, but Not with GVHD after Nonmyeloablative Conditioning for Unrelated Hematopoietic Cell Transplantation.. <i>Blood</i> , 2004, 104, 2753-2753.	0.6	1
126	Treatment for Acute Myelogenous Leukemia by Low Dose Irradiation Based Conditioning and Hematopoietic Cell Transplantation from Related and Unrelated Donors.. <i>Blood</i> , 2004, 104, 3074-3074.	0.6	2

#	ARTICLE	IF	CITATIONS
127	Allogeneic Hematopoietic Cell Transplantation after Fludarabine and 2 Gy Total Body Irradiation for Relapsed and Refractory Mantle Cell Lymphoma.. Blood, 2004, 104, 809-809.	0.6	1
128	Nonmyeloablative Conditioning and Hematopoietic Cell Transplantation (HCT) from HLA-Matched Related or Unrelated Donors for Chemotherapy-Refractory Chronic Lymphocytic Leukemia (CLL).. Blood, 2004, 104, 2323-2323.	0.6	4
129	Graft-versus-Tumor Effects after Allogeneic Hematopoietic Cell Transplantation with Nonmyeloablative Conditioning.. Blood, 2004, 104, 184-184.	0.6	0
130	Non-Myeloablative Allografting from HLA-Identical Sibling Donors for Treatment of CML.. Blood, 2004, 104, 2316-2316.	0.6	1
131	Relapse or progression after hematopoietic cell transplantation using nonmyeloablative conditioning: effect of interventions on outcome. Experimental Hematology, 2003, 31, 974-980.	0.2	26
132	Non-myeloablative allografting from human leucocyte antigen-identical sibling donors for treatment of acute myeloid leukaemia in first complete remission. British Journal of Haematology, 2003, 120, 281-288.	1.2	90
133	Allografting after nonmyeloablative conditioning as a treatment after a failed conventional hematopoietic cell transplant. Biology of Blood and Marrow Transplantation, 2003, 9, 266-272.	2.0	31
134	Predictive factors for outcome of allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia. Biology of Blood and Marrow Transplantation, 2003, 9, 472-481.	2.0	75
135	Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood, 2003, 102, 3912-3918.	0.6	255
136	Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood, 2003, 101, 1620-1629.	0.6	424
137	Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood, 2003, 102, 3447-3454.	0.6	382
138	HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood, 2003, 102, 2021-2030.	0.6	320
139	HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen. Blood, 2003, 102, 31-35.	0.6	168
140	Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood, 2002, 100, 1201-1207.	0.6	278
141	Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. Blood, 2002, 99, 1978-1985.	0.6	220
142	Curative Therapy of Advanced Essential Thrombocythemia or Polycythemia Vera by Hemopoietic Stem Cell Transplantation. Leukemia and Lymphoma, 2002, 43, 1409-1414.	0.6	19
143	Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and fractionated total body irradiation is associated with low relapse rate but considerable nonrelapse mortality. Biology of Blood and Marrow Transplantation, 2002, 8, 161-169.	2.0	66
144	Infectious complications after autologous CD34-selected peripheral blood stem cell transplantation. Biology of Blood and Marrow Transplantation, 2002, 8, 281-289.	2.0	81

#	ARTICLE	IF	CITATIONS
145	Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: A matched control study. <i>Biology of Blood and Marrow Transplantation</i> , 2002, 8, 512-520.	2.0	236
146	Related and unrelated nonmyeloablative hematopoietic stem cell transplantation for malignant diseases. <i>International Journal of Hematology</i> , 2002, 76, 184-189.	0.7	21
147	Granulocyte transfusion therapy for infections in candidates and recipients of HPC transplantation: a comparative analysis of feasibility and outcome for community donors versus related donors. <i>Transfusion</i> , 2002, 42, 1414-1421.	0.8	121
148	Engraftment of early erythroid progenitors is not delayed after non-myeloablative major ABO-incompatible haematopoietic stem cell transplantation. <i>British Journal of Haematology</i> , 2002, 119, 740-750.	1.2	29
149	Nonmyeloablative hematopoietic cell transplantation: status quo and future perspectives. <i>Journal of Clinical Immunology</i> , 2002, 22, 70-74.	2.0	28
150	Relapse after allogeneic bone marrow transplantation for refractory anemia is increased by shielding lungs and liver during total body irradiation. <i>Biology of Blood and Marrow Transplantation</i> , 2001, 7, 163-170.	2.0	26
151	Non-myeloablative hematopoietic stem cell transplantation. <i>Transfusion Clinique Et Biologique</i> , 2001, 8, 231-234.	0.2	22
152	Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. <i>Blood</i> , 2001, 97, 3390-3400.	0.6	1,306
153	Transplantation of Bone Marrow as Compared with Peripheral-Blood Cells from HLA-Identical Relatives in Patients with Hematologic Cancers. <i>New England Journal of Medicine</i> , 2001, 344, 175-181.	13.9	905
154	Drug resistance mechanisms in acute leukemia. <i>Current Opinion in Oncology</i> , 2001, 13, 21-26.	1.1	47
155	CD34 cell dose in granulocyte colony-stimulating factorâ€“mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigenâ€“identical sibling transplantation. <i>Blood</i> , 2001, 98, 3221-3227.	0.6	220
156	Myeloablation and autologous peripheral blood stem cell rescue results in hematologic and clinical responses in patients with myeloid metaplasia with myelofibrosis. <i>Blood</i> , 2001, 98, 586-593.	0.6	70
157	Nonmyeloablative Hematopoietic Cell Transplantation. <i>Annals of the New York Academy of Sciences</i> , 2001, 938, 328-339.	1.8	65
158	Bile Duct Apoptosis and Cholestasis Resembling Acute Graft-Versus-Host Disease After Autologous Hematopoietic Cell Transplantation. <i>American Journal of Surgical Pathology</i> , 2000, 24, 1004-1008.	2.1	55
159	A phase I study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone, etoposide, and the MDR modulator PSC 833: a Southwest Oncology Group study 9617. <i>Leukemia Research</i> , 2000, 24, 567-574.	0.4	58
160	Granulocyte colony-stimulating factor given to donors before apheresis does not prevent aplasia in patients treated with donor leukocyte infusion for recurrent chronic myeloid leukemia after bone marrow transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2000, 6, 321-326.	2.0	32
161	Allogeneic hematopoietic stem cell transplantation: from the nuclear age into the twenty-first century. <i>Transplantation Proceedings</i> , 2000, 32, 2548-2549.	0.3	13
162	A Phase I-II Clinical Trial to Evaluate Removal of CD4 Cells and Partial Depletion of CD8 Cells From Donor Marrow for HLA-Mismatched Unrelated Recipients. <i>Blood</i> , 1999, 94, 2192-2199.	0.6	91

#	ARTICLE	IF	CITATIONS
163	Bone Marrow Transplants from Unrelated Donors for Patients with Chronic Myeloid Leukemia. <i>New England Journal of Medicine</i> , 1998, 338, 962-968.	13.9	602
164	Cyclosporine or Cyclosporine Plus Methylprednisolone for Prophylaxis of Graft-Versus-Host Disease: A Prospective, Randomized Trial. <i>Blood</i> , 1997, 89, 3880-3887.	0.6	127
165	Improved Reconstitution of CD4 T Cells and B Cells But Worsened Reconstitution of Serum IgG Levels After Allogeneic Transplantation of Blood Stem Cells Instead of Marrow. <i>Blood</i> , 1997, 89, 3891-3892.	0.6	44
166	Transplantation of Marrow Cells From Unrelated Donors for Treatment of High-Risk Acute Leukemia: The Effect of Leukemic Burden, Donor HLA-Matching, and Marrow Cell Dose. <i>Blood</i> , 1997, 89, 4226-4235.	0.6	358
167	Allogeneic Peripheral Blood Stem Cell Transplantation May Be Associated With a High Risk of Chronic Graft-Versus-Host Disease. <i>Blood</i> , 1997, 90, 4705-4709.	0.6	303
168	Allogeneic marrow transplantation for primary myelofibrosis and myelofibrosis secondary to polycythaemia vera or essential thrombocytosis. <i>British Journal of Haematology</i> , 1997, 98, 1010-1016.	1.2	66
169	Cyclosporine or Cyclosporine Plus Methylprednisolone for Prophylaxis of Graft-Versus-Host Disease: A Prospective, Randomized Trial. <i>Blood</i> , 1997, 89, 3880-3887.	0.6	3
170	Allogeneic Peripheral Blood Stem Cell Transplantation May Be Associated With a High Risk of Chronic Graft-Versus-Host Disease. <i>Blood</i> , 1997, 90, 4705-4709.	0.6	7